Skip to main content
. Author manuscript; available in PMC: 2012 May 1.
Published in final edited form as: Circ Cardiovasc Qual Outcomes. 2011 Apr 12;4(3):328–336. doi: 10.1161/CIRCOUTCOMES.110.957720

Figure 5.

Figure 5

Hazard ratios of the primary endpoint in women subgroup treated with intensive lipid therapy (Atorvastatin 80) as compared to standard lipid lowering therapy (Pravastatin 40mg) therapy. ERT denotes estrogen replacement therapy. P-interaction=0.27 for menopausal status and lipid therapy; p-interaction=0.75 for ERT and lipid therapy.